Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.42 |
| ▸ | NNMT | P40261 | 1/20 | 0.41 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.40 |
| ▸ | RAB9A | P51151 | 6/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | NPC1 | O15118 | 4/20 | 0.38 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.36 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.36 |
| ▸ | TP53 | P04637 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18298475 | 0.77 | NNMT (0.42) | NNMTPTK2RAB9AMAPTL3MBTL1 | |
| SCHEMBL2759564 | 0.75 | MAPT (0.46) | EGFRPTK2RAB9AMAPTTDP1 | |
| SCHEMBL210400 | 0.75 | KDR (0.53) | NNMTRAB9ATDP1L3MBTL1NPC1 | |
| SCHEMBL29840601 | 0.75 | KDR (0.53) | NNMTRAB9ATDP1L3MBTL1NPC1 | |
| SCHEMBL25758601 | 0.71 | MAP4K1 (0.58) | JAK2JAK1TYK2 | |
| SCHEMBL11964358 | 0.71 | MAPT (0.51) | PTK2RAB9AMAPT | |
| SCHEMBL18308988 | 0.71 | GSK3B (0.47) | NNMTNFKB1NFKB2RELA | |
| SCHEMBL14294323 | 0.70 | NPC1 (0.52) | RAB9AMAPTNPC1TP53SMN1; SMN2 | |
| SCHEMBL11964359 | 0.70 | NPC1 (0.43) | EGFRRAB9AMAPTTDP1L3MBTL1 | |
| SCHEMBL13134206 | 0.69 | RAB9A (0.50) | RAB9AMAPTNPC1TP53SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8088761-B2 | Enzyme inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2012-01-03 | — | — | US | disclosed |
| US-20090247507-A1 | Enzyme Inhibitors | THE INSTITUTE OF CANCER RESEARCH (GB) | 2009-10-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090247507-A1 | Enzyme Inhibitors | AURKC, AURKB, AURKA | EGFR 50/4885NNMT 207/4885PTK2 844/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.